A Phase 3 interventional study of Placebo and Brexpiprazole in Schizophrenia, sponsored by H. Lundbeck A/S. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-03-16.
Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing brexpiprazole in Schizophrenia — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Schizophrenia.
Among the 28 studies testing brexpiprazole in Schizophrenia, this one is the 5th largest by enrollment, is one of 6 that started in 2013, is one of 16 in phase 3, and was the 13th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →1 of the 28 studies testing brexpiprazole in Schizophrenia is open now. Recruiting first, the newest first:
New York State Psychiatric Institute
Ages 18–55
brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 17 · Phase 4 1
First in 2008; this study’s year is marked. 6 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 468 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 155 across the 28 interventional studies. Of the 26 that completed or were terminated, 22 (85%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 28 have an industry lead sponsor. The 7 most frequent:
H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
29 studies in Schizophrenia by H. Lundbeck A/S: none open now, none under way, none of them phase 3. Of 28 finished, 9 (32%) have results posted.
Among the 29 studies in Schizophrenia by H. Lundbeck A/S, this one is the 4th largest by enrollment of the 28 interventional ones that give a count, is one of 6 that started in 2013, is one of 16 in phase 3, and was the 16th registered.
H. Lundbeck A/S’s Schizophrenia studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing brexpiprazole in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among H. Lundbeck A/S’s 29 in Schizophrenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To determine the efficacy and safety of brexpiprazole for the treatment of adults experiencing an acute episode of schizophrenia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other inclusion and exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo
Patients randomised to brexpiprazole received 1mg/day on Day 1, 2mg/day on Day 2, 3mg/day on Day 3 (uptitration); the dose could be adjusted from Day 4 onwards to 2, 3, or 4mg/day to optimise the clinical effect and tolerability.
Drug: Brexpiprazole
Active Reference. Patients randomised to quetiapine received 300mg/day on Day 1, 600mg/day on Days 2 and 3 (uptitration); the dose could be adjusted from Day 4 onwards to 400, 600, or 800mg/day to optimise the clinical effect and tolerability.
Drug: Quetiapine extended release
Once daily as tablets and capsules, orally
2-4 mg/day, once daily, tablets, orally
400-800 mg/day, once daily, encapsulated tablets, orally
Also known as: Seroquel XL®/XR®
Change From Baseline to Week 6 in PANSS Total Score
The Positive and Negative Syndrome Scale (PANSS) is a 30-item scale for assessing the symptoms of schizophrenia. For each PANSS item, symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. The PANSS total score (30 items) ranged from 30 to 210 with a higher score indicating greater severity of symptoms.
Time frame: Baseline and Week 6
Change From Baseline to Week 6 in CGI-S Score
The Clinical Global Impression - Severity of Illness (CGI-S) provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill patients).
Time frame: Baseline and Week 6
CGI-I Score at Week 6
The Clinical Global Impression - Global Improvement (CGI-I) provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). In all cases, the assessment should be made independent of whether the rater believes the improvement is drug-related or not.
Time frame: Week 6
Change From Baseline to Week 6 in PANSS Positive Subscale Score
The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Positive Subscale score is calculated from 7 items (for example: delusions, conceptual disorganization and hallucinatory behaviour). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms
Time frame: Baseline and Week 6
Change From Baseline to Week 6 in PANSS Negative Subscale Score
The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Negative Subscale score is calculated from 7 items (for example: blunted affect, emotional withdrawal and poor rapport). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms
Time frame: Baseline and Week 6
Change From Baseline to Week 6 in PANSS General Psychopathology Subscale Score
The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS General Psychopathology Subscale score is calculated from 16 items (for example: somatic concern, anxiety and guilt feelings). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms
Time frame: Baseline and Week 6
Change From Baseline to Week 6 in PANSS Excited Component Score
The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Excited Component score is calculated from 5 items (for example: poor impulse control, tension and hostility). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms
Time frame: Baseline and Week 6
Change From Baseline to Week 6 in PANSS Marder Factor Scores: Negative Symptoms
The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Marder Factor scores: negative symptoms is calculated from 7 items (for example: blunted affect, emotional withdrawal and motor retardation). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms
Time frame: Baseline and Week 6
Change From Baseline to Week 6 in PANSS Marder Factor Scores: Positive Symptoms
The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Marder Factor scores: positive symptoms is calculated from 8 items (for example: delusions, conceptual disorganization and stereotype thinking). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms
Time frame: Baseline and Week 6
Change From Baseline to Week 6 in PANSS Marder Factor Scores: Disorganized Thoughts
The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Marder Factor scores: disorganized thoughts is calculated from 7 items (for example: conceptual disorganization, difficulty in abstract thinking and mannerisms and posturing). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms
Time frame: Baseline and Week 6
Change From Baseline to Week 6 in PANSS Marder Factor Scores: Uncontrolled Hostility/Excitement
The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Marder Factor scores: uncontrolled hostility/excitement is calculated from 4 items (for example: excitement, hostility, and uncooperativeness).Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms
Time frame: Baseline and Week 6
Change From Baseline to Week 6 in PANSS Marder Factor Scores: Anxiety/Depression
The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Marder Factor scores: anxiety/depression is calculated from 4 items (for example: anxiety, guilt feelings, and tension). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms
Time frame: Baseline and Week 6
Discontinuation Due to Lack of Efficacy During the Study
Discontinuation due to lack of efficacy was based on the primary reason for withdrawal
Time frame: Baseline to Week 6
Response Rate at Week 6
The response rate was defined as a reduction of ≥30% from baseline in PANSS total score OR a CGI-I score of 1 or 2
Time frame: Baseline and Week 6
Change From Baseline to Week 6 in PSP Total Score
The Personal and Social Performance Scale (PSP) is a clinician-rated scale designed and validated to measure a patient's current level of social functioning. The PSP scale consists of a 100-point single-item rating scale, subdivided into 10 equal intervals. Scores of 1 to 10 indicate lack of autonomy in basic functioning, whereas scores of 91 to 100 reflect excellent functioning. The total score is rated by the investigator and is based on an algorithm which takes both the ratings of the 4 primary domains of PSP, and the combination of these ratings into account. The 4 primary domains are: socially useful activities (including work and study), personal and social relationships, self-care, and disturbing and aggressive behaviours. The 4 domains are assessed on a 6-point scale, from absent to very severe. A higher score indicates a better performance.
Time frame: Baseline and Week 6
PSP Functional Remission Rate at Week 6
The PSP functional remission rate was defined as a PSP total score ≥71
Time frame: Week 6
PSP Functional Response Rate at Week 6
The PSP functional response rate was defined as ≥10 point improvement from Baseline on the PSP total score
Time frame: Week 6
PSP Domain D: Disturbing and Aggressive Behaviours at Week 6
PSP domain D: disturbing and aggressive behaviours were categorised as "aggressive" (corresponding to mild, manifest, marked, severe, or very severe) or "nonaggressive" (corresponding to absent)
Time frame: Week 6
| Milestone | Placebo | Brexpiprazole | Quetiapine Extended Release |
|---|---|---|---|
| Started | 163 | 151 | 154 |
| Treated | 161 | 150 | 153 |
| Completed | 108 | 113 | 122 |
| Not completed | 55 | 38 | 32 |
| Withdrew: Randomised not treated | 2 | 1 | 1 |
| Withdrew: Adverse event | 11 | 14 | 4 |
| Withdrew: Lack of efficacy | 24 | 10 | 11 |
| Withdrew: Protocol violation | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 6 | 0 | 6 |
| Withdrew: Administrative or other reasons | 11 | 13 | 9 |
The Positive and Negative Syndrome Scale (PANSS) is a 30-item scale for assessing the symptoms of schizophrenia. For each PANSS item, symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. The PANSS total score (30 items) ranged from 30 to 210 with a higher score indicating greater severity of symptoms.
| units on a scale | Placebo | Brexpiprazole | Quetiapine Extended Release |
|---|---|---|---|
| Change From Baseline to Week 6 in PANSS Total Score | -15.9 ± 1.5 | -20.0 ± 1.5 | -24.0 ± 1.5 |
The Clinical Global Impression - Severity of Illness (CGI-S) provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill patients).
| units on a scale | Placebo | Brexpiprazole | Quetiapine Extended Release |
|---|---|---|---|
| Change From Baseline to Week 6 in CGI-S Score | -0.9 ± 0.1 | -1.2 ± 0.1 | -1.4 ± 0.1 |
The Clinical Global Impression - Global Improvement (CGI-I) provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). In all cases, the assessment should be made independent of whether the rater believes the improvement is drug-related or not.
| units on a scale | Placebo | Brexpiprazole | Quetiapine Extended Release |
|---|---|---|---|
| CGI-I Score at Week 6 | 3.0 ± 0.1 | 2.7 ± 0.1 | 2.5 ± 0.1 |
The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Positive Subscale score is calculated from 7 items (for example: delusions, conceptual disorganization and hallucinatory behaviour). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms
| units on a scale | Placebo | Brexpiprazole | Quetiapine Extended Release |
|---|---|---|---|
| Change From Baseline to Week 6 in PANSS Positive Subscale Score | -5.4 ± 0.5 | -7.0 ± 0.5 | -8.1 ± 0.5 |
The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Negative Subscale score is calculated from 7 items (for example: blunted affect, emotional withdrawal and poor rapport). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms
| units on a scale | Placebo | Brexpiprazole | Quetiapine Extended Release |
|---|---|---|---|
| Change From Baseline to Week 6 in PANSS Negative Subscale Score | -3.1 ± 0.4 | -3.7 ± 0.4 | -4.5 ± 0.4 |
The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS General Psychopathology Subscale score is calculated from 16 items (for example: somatic concern, anxiety and guilt feelings). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms
| units on a scale | Placebo | Brexpiprazole | Quetiapine Extended Release |
|---|---|---|---|
| Change From Baseline to Week 6 in PANSS General Psychopathology Subscale Score | -8.2 ± 0.7 | -9.9 ± 0.7 | -11.6 ± 0.7 |
The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Excited Component score is calculated from 5 items (for example: poor impulse control, tension and hostility). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms
| units on a scale | Placebo | Brexpiprazole | Quetiapine Extended Release |
|---|---|---|---|
| Change From Baseline to Week 6 in PANSS Excited Component Score | -2.5 ± 0.3 | -3.3 ± 0.3 | -3.9 ± 0.3 |
The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Marder Factor scores: negative symptoms is calculated from 7 items (for example: blunted affect, emotional withdrawal and motor retardation). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms
| units on a scale | Placebo | Brexpiprazole | Quetiapine Extended Release |
|---|---|---|---|
| Change From Baseline to Week 6 in PANSS Marder Factor Scores: Negative Symptoms | -3.6 ± 0.4 | -4.3 ± 0.4 | -4.8 ± 0.4 |
The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Marder Factor scores: positive symptoms is calculated from 8 items (for example: delusions, conceptual disorganization and stereotype thinking). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms
| units on a scale | Placebo | Brexpiprazole | Quetiapine Extended Release |
|---|---|---|---|
| Change From Baseline to Week 6 in PANSS Marder Factor Scores: Positive Symptoms | -5.7 ± 0.5 | -7.1 ± 0.5 | -8.4 ± 0.5 |
The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Marder Factor scores: disorganized thoughts is calculated from 7 items (for example: conceptual disorganization, difficulty in abstract thinking and mannerisms and posturing). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms
| units on a scale | Placebo | Brexpiprazole | Quetiapine Extended Release |
|---|---|---|---|
| Change From Baseline to Week 6 in PANSS Marder Factor Scores: Disorganized Thoughts | -3.2 ± 0.4 | -4.0 ± 0.4 | -4.8 ± 0.3 |
The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Marder Factor scores: uncontrolled hostility/excitement is calculated from 4 items (for example: excitement, hostility, and uncooperativeness).Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms
| units on a scale | Placebo | Brexpiprazole | Quetiapine Extended Release |
|---|---|---|---|
| Change From Baseline to Week 6 in PANSS Marder Factor Scores: Uncontrolled Hostility/Excitement | -1.8 ± 0.3 | -2.5 ± 0.3 | -2.8 ± 0.3 |
The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Marder Factor scores: anxiety/depression is calculated from 4 items (for example: anxiety, guilt feelings, and tension). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms
| units on a scale | Placebo | Brexpiprazole | Quetiapine Extended Release |
|---|---|---|---|
| Change From Baseline to Week 6 in PANSS Marder Factor Scores: Anxiety/Depression | -2.9 ± 0.2 | -3.2 ± 0.2 | -3.6 ± 0.2 |
Discontinuation due to lack of efficacy was based on the primary reason for withdrawal
| percentage of patients | Placebo | Brexpiprazole | Quetiapine Extended Release |
|---|---|---|---|
| Discontinuation Due to Lack of Efficacy During the Study | 14.91 | 6.67 | 7.19 |
The response rate was defined as a reduction of ≥30% from baseline in PANSS total score OR a CGI-I score of 1 or 2
| percentage of responders | Placebo | Brexpiprazole | Quetiapine Extended Release |
|---|---|---|---|
| Response Rate at Week 6 | 32.1 | 48.7 | 62.7 |
The Personal and Social Performance Scale (PSP) is a clinician-rated scale designed and validated to measure a patient's current level of social functioning. The PSP scale consists of a 100-point single-item rating scale, subdivided into 10 equal intervals. Scores of 1 to 10 indicate lack of autonomy in basic functioning, whereas scores of 91 to 100 reflect excellent functioning. The total score is rated by the investigator and is based on an algorithm which takes both the ratings of the 4 primary domains of PSP, and the combination of these ratings into account. The 4 primary domains are: socially useful activities (including work and study), personal and social relationships, self-care, and disturbing and aggressive behaviours. The 4 domains are assessed on a 6-point scale, from absent to very severe. A higher score indicates a better performance.
| units on a scale | Placebo | Brexpiprazole | Quetiapine Extended Release |
|---|---|---|---|
| Change From Baseline to Week 6 in PSP Total Score | 9.4 ± 1.0 | 13.0 ± 1.0 | 15.3 ± 1.0 |
The PSP functional remission rate was defined as a PSP total score ≥71
| percentage of remitters | Placebo | Brexpiprazole | Quetiapine Extended Release |
|---|---|---|---|
| PSP Functional Remission Rate at Week 6 | 5.7 | 9.6 | 14.4 |
The PSP functional response rate was defined as ≥10 point improvement from Baseline on the PSP total score
| percentage of responders | Placebo | Brexpiprazole | Quetiapine Extended Release |
|---|---|---|---|
| PSP Functional Response Rate at Week 6 | 36.3 | 53.4 | 64.4 |
PSP domain D: disturbing and aggressive behaviours were categorised as "aggressive" (corresponding to mild, manifest, marked, severe, or very severe) or "nonaggressive" (corresponding to absent)
| percentage of aggressive patients | Placebo | Brexpiprazole | Quetiapine Extended Release |
|---|---|---|---|
| PSP Domain D: Disturbing and Aggressive Behaviours at Week 6 | 30.4 | 27.2 | 22.2 |
Collected over Baseline to end of treatment (Week 6). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 6/161 (3.7%) | 44/161 (27.3%) |
| Brexpiprazole | — | 7/150 (4.7%) | 48/150 (32%) |
| Quetiapine | — | 2/153 (1.3%) | 73/153 (47.7%) |
| Event | Placebo | Brexpiprazole | Quetiapine |
|---|---|---|---|
| SchizophreniaPsychiatric disorders | 4/161 | 3/150 | 1/153 |
| Type 2 diabetes mellitusMetabolism and nutrition disorders | 0/161 | 1/150 | 0/153 |
| Grand mal convulsionNervous system disorders | 0/161 | 1/150 | 0/153 |
| Suicide attemptPsychiatric disorders | 0/161 | 1/150 | 0/153 |
| AngioedemaSkin and subcutaneous tissue disorders | 0/161 | 1/150 | 0/153 |
| Psychotic disorderPsychiatric disorders | 1/161 | 0/150 | 1/153 |
| AnxietyPsychiatric disorders | 1/161 | 0/150 | 0/153 |
| Schizophrenia, paranoid typePsychiatric disorders | 1/161 | 0/150 | 0/153 |
| Event | Placebo | Brexpiprazole | Quetiapine |
|---|---|---|---|
| SomnolenceNervous system disorders | 8/161 | 7/150 | 34/153 |
| Weight increasedInvestigations | 6/161 | 8/150 | 20/153 |
| DizzinessNervous system disorders | 1/161 | 4/150 | 18/153 |
| InsomniaPsychiatric disorders | 10/161 | 13/150 | 4/153 |
| Dry mouthGastrointestinal disorders | 2/161 | 2/150 | 13/153 |
| HeadacheNervous system disorders | 11/161 | 8/150 | 9/153 |
| SchizophreniaPsychiatric disorders | 11/161 | 6/150 | 4/153 |
| AkathisiaNervous system disorders | 4/161 | 9/150 | 6/153 |
| SedationNervous system disorders | 5/161 | 4/150 | 8/153 |
all-patients-treated set (APTS)
| Age, Continuous(years) | Placebo | Brexpiprazole | Quetiapine Extended Release | Total |
|---|---|---|---|---|
| Mean | 40.85 ± 10.56 | 39.68 ± 10.87 | 41.12 ± 10.91 | 40.56 ± 10.77 |
| Sex: Female, Male(Participants) | Placebo | Brexpiprazole | Quetiapine Extended Release | Total |
|---|---|---|---|---|
| Female | 70 | 66 | 64 | 200 |
| Male | 91 | 84 | 89 | 264 |
| Race (NIH/OMB)(Participants) | Placebo | Brexpiprazole | Quetiapine Extended Release | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 1 |
| Asian | 2 | 1 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 | 2 |
| Black or African American | 35 | 33 | 38 | 106 |
| White | 123 | 113 | 113 | 349 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 2 | 1 | 3 |
| Region of Enrollment(participants) | Placebo | Brexpiprazole | Quetiapine Extended Release | Total |
|---|---|---|---|---|
| United States | 50 | 52 | 56 | 158 |
| Estonia | 4 | 3 | 4 | 11 |
| France | 1 | 0 | 1 | 2 |
| Poland | 5 | 5 | 5 | 15 |
| Romania | 14 | 13 | 11 | 38 |
| Serbia | 13 | 11 | 11 | 35 |
| Slovakia | 1 | 1 | 1 | 3 |
| Ukraine | 30 | 28 | 29 | 87 |
| Russian Federation | 43 | 37 | 35 | 115 |
| Time since schizophrenia diagnosis (years)(years) | Placebo | Brexpiprazole | Quetiapine Extended Release | Total |
|---|---|---|---|---|
| Mean | 14.15 ± 9.35 | 12.88 ± 9.43 | 13.78 ± 9.49 | 13.62 ± 9.42 |
| Time since first antipsychotic treatment (years)(years) | Placebo | Brexpiprazole | Quetiapine Extended Release | Total |
|---|---|---|---|---|
| Mean | 14.48 ± 8.98 | 13.43 ± 9.19 | 14.31 ± 9.34 | 14.08 ± 9.16 |
| PANSS total score(units on a scale) | Placebo | Brexpiprazole | Quetiapine Extended Release | Total |
|---|---|---|---|---|
| Mean | 98.38 ± 10.30 | 97.82 ± 10.25 | 98.82 ± 10.83 | 98.34 ± 10.45 |
| CGI-S Score(units on a scale) | Placebo | Brexpiprazole | Quetiapine Extended Release | Total |
|---|---|---|---|---|
| Mean | 4.94 ± 0.57 | 4.96 ± 0.59 | 4.98 ± 0.57 | 4.96 ± 0.58 |
The record gives a start of Mar 2013, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2016, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brexpiprazole